Something for everyone, page-20

I might have given you a bum steer there Hesk. I can't actually find anything from that company in the last 6-12 months that gave a timetable towards now so I don't think anything has specifically been pushed out. The Euroz report is where the 'late this year / early next year' comment is madeabout a pre-clinical timetable and it is probably in the other reports. This may still be consistent as my consensus was H2 2017 (but hoped that might mean now!). It might be worth a re-read of the thorough SR report as that might have a hint on timelines - both these analysts would have had proper sit downs with the company although the Euroz report reads more like they are guessing some things so SRs report might be the only one from 'inside the tent' so to speak.

As for what the catalyst might be? No idea - I'd be happy with a CEO! (RH left on July 18th) From what I have observed the Chair has been operating more as an exec chair and we know Kendall was in an advisory capacity prior to joining the Board so it seems the Board is highly involved in the day to day - that is fine but the next 12-24 months are going to require full time attention IMHO so I'd be happy with any clarity on that front.

There are 6 MTAs out and some are more than 6 months old so we could get a left field announcement on anything. They have become fairly tight on providing a quarterly update (last 2 have been just before and just after quarter end although the Dec one was probably early because of a Christmas break) so I expect we will know more in about 3 weeks regardless.

On the tech side the MACD threatens to cross and Fibbo retracement is sufficient at 50% but could do a full 61.8% down to 3.6/3.7c before the up move. Certainly looks like a liquidity point if anyone wants to sell prior to June 30 for some reason.